ArticleBlood advances2026
Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
abstractAlthough obesity is an established modifiable risk factor for multiple myeloma (MM), the influence of obesity on survival among Black patients, among whom obesity and MM are more common, is less clear. We evaluated the association of body mass index (BMI) with progression free survival and overall survival among 834 histologically confirmed patients with newly diagnosed MM (NDMM) enrolled in the Integrative Molecular And Genetic Epidemiology study between 2009 and 2020. We estimated the association of BMI with the risk for progressed disease and all-cause and MM-specific mortality using hazard ratios (HR) and corresponding 95% confidence intervals (CI), calculated from multivariable Cox proportional hazard models adjusted for prognostic factors. When compared with NDMM patients with a normal BMI at diagnosis (18.5-24.9 kg/m2) positive associations with all-cause mortality were observed at the extremes with a 52% and 147% increased risk for death in patients with underweight (BMI, <18.5 kg/m2, HR, 1.52; 95% CI 0.48-4.84) and those with obesity (BMI, ≥30.0 kg/m2, HR, 2.47; 95% CI, 1.26-4.85), respectively. Patients with severe obesity (BMI, ≥35kg/m2) had the highest risk when compared with those with a normal BMI (HR, 3.14; 95% CI, 1.50-6.55), particularly among White (HR, 3.22; 95% CI, 1.30-7.94) and female (HR, 4.17; 95% CI, 1.20-14.47) patients with NDMM; however, the differences by race and sex were not statistically significant (Pinteraction ≥.60). Severe obesity was also associated with an 83% elevated risk for progressed disease among patients with NDMM (HR, 1.83; 95% CI, 1.04-3.24). These findings were similar for MM-specific mortality and highlight weight management as a potential strategy to improve the prognosis of all patients with NDMM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.